Interleukin-15 (IL-15) and IL-21 have been reported to support the function of anti-tumor T cells. However, their use in the clinic has been constrained, in part, by dose-limiting toxicity and the need for repeated administration. To overcome these limitations, researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) have developed synthetic IL-15 and IL-21 molecules for autocrine expression by the engineered therapeutic T cells. These molecules were designed with flexible linkers that connect to cell membrane anchors. This, in turn, reduces systemic toxicity caused by free cytokine molecules. The inventors have shown that co-expression of the novel IL-15 and IL-21 tethered molecules improves the anti-tumor efficacy of the therapeutic engineered T cells in vivo.
- Treatment of cancer patients receiving T cell-based immunotherapy
- T cells that co-express the tethered IL-15 and IL-21 on their cell membrane can increase therapeutic effectiveness of adoptive immunotherapy because it can reduce systemic toxicity caused by free cytokine molecules
- T cells that co-express the tethered IL-15 and IL-21 on their cell membrane are already known to have a greater decrease in tumor size compared to those mice treated with T cell-based immunotherapies using unmodified T cells
Christian Hinrichs (NCI), Benjamin Jin (NCI)
- U.S. Provisional: U.S. Provisional Patent Application Number 62/628,454 , Filed 09 Feb 2018